Careful interpretation of our findings is needed, however, because the pCR rate for the chemotherapy alone group was calculated from results in IBC patients with all breast cancer subtypes, whereas the pCR rate for anti-HER2 plus chemotherapy was calculated from results specifically in patients with HER2-positive IBC. This evidence concerns the gene ERBB2 and breast cancer.